Developer seeks collaborators to advance potential coronavirus treatment

By Vassia Barba

- Last updated on GMT

(Image: Getty/kieferpix)
(Image: Getty/kieferpix)

Related tags Coronavirus COVID-19 Cancer

Bold is on the hunt for supporters among the industry to help evaluate its investigational anti-cancer therapy as a potential coronavirus treatment, after seeing related elements.

Bold Therapeutics is a clinical-stage biopharmaceutical company working on the development of oncology therapies, with its lead candidate being BOLD-100, an anti-resistance ruthenium-based small-molecule drug.

The company suggests that BOLD-100, which has just demonstrated positive results as a treatment for advanced gastrointestinal cancers in Phase I clinical trials, shows potential utility as a novel antiviral agent.

Therefore, Bold intends to examine the drug as a potential treatment for coronavirus, and join the pharmaceutical industry in the race to develop effective treatments to tackle the ongoing pandemic.

The company suggests that it holds ‘ample’ quantity of current good manufacturing practice clinical product available, as well as an open investigational new drug (IND) application in the US and Canada, respectively, allowing for potentially rapid clinical development.

However, Bold states that its clinical and scientific capability has been built to address drug resistance in cancer, and not interventions for COVID-19.

Amid the ongoing pandemic, the developer announced that it is ‘urgently’ seeking expressions of interest from collaborators who have the capability and resources to enable rapid advancement of BOLD-100 as a treatment of COVID-19.

Promising evidence

Bold’s suggestions of the drug’s potential effectiveness are based on the candidate’s main mechanism of action, which is to inhibit stress-induced upregulation of GRP78 protein.

According to the company, GRP78 is a common receptor for viral recognition of host cells, while a recent publication​ identified the protein as a potential binding site for COVID-19.

Moreover, other published literature has suggested that inhibiting or blocking GPR78 can reduce viral loads or viral replication in Ebola, Japanese Encephalitis Virus and Dengue Virus.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers